We will perform a randomized clinical trial with minocycline. Minocycline is an antibiotic of the tetracycline family and known to modulate inflammation, gelatinase activity and angiogenesis, which we know are central mechanisms in CAA-pathology. Our aim is to prove in a randomized clinical trial in a translational setting that minocycline treatment (duration 3 months) can decrease markers of neuroinflammation and the gelatinase pathway in the cerebrospinal fluid (CSF) of persons with D-CAA (n=30) and sporadic-CAA (n=30).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
60
100 mg twice daily for 3 months
twice daily for 3 months
Leiden University Medical Center
Leiden, Netherlands
RECRUITINGinflammatory, vessel integrity and gelatinase pathway associated biomarkers in CSF
IL6, MCP-1, IBA-1, MMP2/9, and VEGF
Time frame: 3 months
safety and tolerability of minocycline
side effects and adverse events
Time frame: 3 months
progression of hemorrhagic markers on 7T MRI before and after treatment
cSS, cortical microbleeds
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.